0.74
+0.1478(+25.16%)
Currency In USD
| Previous Close | 0.59 |
| Open | 0.79 |
| Day High | 0.83 |
| Day Low | 0.71 |
| 52-Week High | 74.38 |
| 52-Week Low | 0.57 |
| Volume | 78.56M |
| Average Volume | 5.92M |
| Market Cap | 2.45M |
| PE | -0.01 |
| EPS | -82.8 |
| Moving Average 50 Days | 2.36 |
| Moving Average 200 Days | 10.76 |
| Change | 0.13 |
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
A leading AI and humanoid robotics company has commercially available models designed, built and manufactured in the United States of America CINCINNATI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Compa
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.
GlobeNewswire Inc.
Sep 26, 2025 12:30 PM GMT
CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) ("Onconetix" or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
GlobeNewswire Inc.
Sep 26, 2025 12:15 PM GMT
CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in op